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Abstract
Background: Duchenne muscular dystrophy (DMD) is a devastating muscle wasting disease caused by mutations in
dystrophin, a muscle cytoskeletal protein. Utrophin is a homologue of dystrophin that can functionally compensate for its
absence when expressed at increased levels in the myofibre, as shown by studies in dystrophin-deficient mice. Utrophin
upregulation is therefore a promising therapeutic approach for DMD. The use of a small, drug-like molecule to achieve
utrophin upregulation offers obvious advantages in terms of delivery and bioavailability. Furthermore, much of the time
and expense involved in the development of a new drug can be eliminated by screening molecules that are already
approved for clinical use.
Methodology/Principal Findings: We developed and validated a cell-based, high-throughput screening assay for utrophin
promoter activation, and used it to screen the Prestwick Chemical Library of marketed drugs and natural compounds. Initial
screening produced 20 hit molecules, 14 of which exhibited dose-dependent activation of the utrophin promoter and were
confirmed as hits. Independent validation demonstrated that one of these compounds, nabumetone, is able to upregulate
endogenous utrophin mRNA and protein, in C2C12 muscle cells.
Conclusions/Significance: We have developed a cell-based, high-throughput screening utrophin promoter assay. Using this
assay, we identified and validated a utrophin promoter-activating drug, nabumetone, for which pharmacokinetics and
safety in humans are already well described, and which represents a lead compound for utrophin upregulation as a therapy
for DMD.
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Introduction
Duchenne muscular dystrophy (DMD) is a devastating X-linked
muscle wasting disease, caused by mutations in the dystrophin
gene [1,2]. Dystrophin provides structural integrity to skeletal and
cardiac muscle by linking the subsarcolemmal actin cytoskeleton to
the extracellular matrix, via the dystrophin associated protein
complex (DAPC). In the absence of dystrophin, the entire DAPC
is lost from the sarcolemma [3]. Muscles are unable to transmit
force efficiently and become susceptible to damage during
contraction, leading to cycles of degeneration and regeneration.
Eventually, regeneration fails and muscle fibres are replaced by
fatty and fibrous tissue [2]. Calcium misregulation and chronic
inflammation are also thought to contribute to the phenotype
[4,5,6]. For patients, DMD leads to progressive muscle weakness,
dependence on a wheelchair, respiratory and cardiac complica-
tions and a shortened lifespan [7,8]. There is currently no effective
treatment available.
Utrophin is an autosomal homologue of dystrophin that can
also bind to proteins of the DAPC [9,10,11,12]. Dystrophin and
utrophin share 74% similarity at the amino acid level and have
very similar domain structures [12,13]. Utrophin is expressed in
place of dystrophin in foetal muscle, but in adult myofibres is
confined to the neuromuscular and myotendinous junctions.
Utrophin is also expressed in other tissues including lung, kidney
and liver [9,14]. There are two isoforms of utrophin, A and B, that
are transcribed from different promoters [15]. Utrophin A is the
predominant isoform in the myofibre [16]. Studies in mdx mice, a
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in myofibres by viral vector-mediated delivery or by transgenic
means, can compensate for the absence of dystrophin, restoring
normal muscle function [17,18]. It is also worth noting that,
because utrophin is expressed in foetal muscle and in various non-
muscle tissues in the adult [9,10], its overexpression in the muscles
of people with DMD is unlikely to provoke an immune response.
Utrophin upregulation is therefore an attractive therapeutic
approach for DMD. Preclinical investigations of utrophin-
upregulating treatments, such as heregulin, L-arginine, viral
delivery of an artificial transcription factor targeting the utrophin
promoter or direct administration of a TAT-tagged ‘microutro-
phin’ protein have yielded promising improvements in the mdx
phenotype [19,20,21,22,23]. However, no utrophin upregulation
therapy is yet available for clinical use in DMD patients.
In contrast to protein or virus-based therapeutics, a small-
compound drug for utrophin upregulation would avoid potential
obstacles in terms of delivery, safety and regulatory body approval.
The process of drug discovery, from high-throughput screening
through lead optimisation, in vivo studies, clinical trials and
eventual approval for patient use, is protracted and expensive,
with high failure rates [24,25,26]. An accelerated passage to the
clinic and an improved chance of success could be achieved by
screening compounds that are already approved for other
indications [27,28,29]. Indeed, this approach was successful in
identifying b-lactam antibiotics as potential new drugs for
amyotrophic lateral sclerosis [30]. With this in mind, we developed
a cell-based, high-throughput assay for utrophin A promoter
activation, and used it to screen the Prestwick Chemical Library,
which comprises 90% approved drugs and 10% natural
compounds. Initial screening generated 20 hits out of 1120
compounds (1.8%). Further testing for dose-dependent utrophin
promoter activation confirmed 14 molecules as hits, one of which,
nabumetone, was shown to upregulate endogenous utrophin A
mRNA and protein, in independent validation experiments using
the C2C12 muscle cell line. This drug, for which pharmacokinet-
ics, bioavailability and safety in humans are already well described,
represents a potential therapeutic candidate for DMD.
Methods
Chemicals
Trichostatin A (TSA) was purchased from Wako; a stock
solution of 0.1 mg/ml (331 mM) was prepared by dissolving in
methanol. Heregulin-b1 EGF domain was purchased from R&D
systems; a 1.25 mM stock solution was prepared by dissolving in
sterile PBS supplemented with 0.1% bovine serum albumin. L-
arginine was purchased from Sigma; a 100 mg/ml (574 mM)
stock solution was made by dissolving in sterile water. Okadaic
acid was purchased from Sigma; a stock solution of 20 mM was
made by dissolving in DMSO. The Prestwick Chemical Library
was purchased from Prestwick Chemical. The 1120 compounds
were supplied at 2 mg/ml in DMSO, in 96-well format. For
screening, the library was reformatted to 384-well format.
Cell Culture
C2C12 cells (purchased from ATCC) were cultured in high
glucose DMEM with 10% foetal bovine serum (FBS), 2 mM L-
glutamine, 100 U/ml penicillin and 0.1 mg/ml streptomycin. Cell
culture reagents were purchased from Gibco. For the C2C12utrn
stable cell line, 250 mg/ml hygromycin B (Roche) was added to
the media. Cells were plated at 1200 cells/well in 384-well plates,
3000 cells/well in 96-well plates or 60 000 cells/well in 6-well
plates. For 384-well plates, cells were seeded using a Matrix
Wellmate (Thermo Scientific).
Luciferase Assays
Luciferase assays were done using the BrightGlo assay
(Promega), following the manufacturer’s instructions. For assays
done in 96-well format, luminescence was recorded using a
Luminoskan Ascent luminometer (Thermo Labsystems). For
assays done in 384-well format, luminescence was recorded using
an Envision plate reader (Perkin Elmer).
Cell Interference Assay
QuantiLum recombinant luciferase (Promega) diluted in C2C12
media was added to 96-well plates with or without C2C12 cells at
concentrations of 10
29 to 10
214 M (50 ml/well). Luciferase
activity was assayed as described above. Statistical analysis was
done by two-way ANOVA, using GraphPad Prism 4 (GraphPad
Software, Inc).
Generation of pGL4:14/utrnAprom Construct
The 2.3 kb human utrophin A promoter fragment was
amplified by PCR from CHORI BAC clone PR1-91J24 (EMBL
accession no. AL024474), using the primers 59-TCAAACACTC-
CAATGTGGCCTTATTATCTA-39 and 59-TAAAGCTTGGA-
GAAGCAGACACGAAC-39. The PCR product was TA-cloned
into the pCR2.1-TOPO vector (Invitrogen) and completely
sequenced before subcloning into the multiple cloning site of
pGL4:14 (Promega) using the restriction enzymes KpnI and EcoRI,
to generate the construct pGL4:14/utrnAprom.
Generation of C2C12utrn Stable Cell Line
C2C12 cells were transfected with the pGL4:14/utrnAprom
construct using Lipofectamine2000 (Invitrogen), following the
manufacturer’s instructions. After 24 hours, media was changed
and after 48 hours, cells were trypsinised and re-plated in media
supplemented with 250 mg/ml hygromycin B. Resistant colonies
were removed using filter paper and cells were re-plated in 96-well
plates with sequential dilution so that cell numbers decreased to 0
across multiple wells. From the wells with the lowest starting cell
number in which cells survived and multiplied, cells were
harvested and subjected to a second round of plating with
sequential dilution. The wells with the lowest starting cell number
were again selected and clones were expanded into 24-well plates.
Validation of C2C12utrn Stable Cell Line
C2C12utrn clones were first validated using the BrightGlo
luciferase assay (Promega). From the four clones with the highest
luciferase activity, genomic DNA was isolated using the Archive-
Pure DNA Cell/Tissue Kit (5Prime, Inc). For PCR validation, the
primers 59-ACTCTGGAGCGCGCGCCCCA-39 and 59-
CGCCTCTGCAGCGCTCCGGCTC-39, which bind specifically
to the utrophin A promoter, were used for amplification from
300 ng of genomic DNA. The validated clone with the highest
luciferase activity was used for all subsequent experiments.
DMSO Toxicity and Positive Control Evaluation
For evaluation of sensitivity to DMSO, C2C12utrn cells were
seeded in 96-well plates and treated with DMSO (Sigma) at final
concentrations of 0–0.5%. Luciferase activity was assayed after
48 hours, as described above.
For evaluation of potential positive controls, C2C12utrn cells
were seeded in 96-well plates 24 hours prior to compound
treatment. Cells were exposed to L-arginine (2 mM), TSA
HTS for Utrophin Promoter Activation
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48 hours before assaying luciferase activity. Differences between
treatments were tested by one-way ANOVA using Statview
software (SAS Institute, Inc). Statistical robustness was assessed by
Z-factor, defined as 12((36(SD control+SD treated))/(mean
treated2mean control)) and percentage covariance (% CV).
For generation of the TSA dose-response curve, C2C12utrn
cells were plated in 384-well plates 24 hours prior to treatment
with TSA. Five dilutions of TSA from 0.3 to 5000 mM were
prepared in 100% DMSO. TSA was added to cells at final
concentrations ranging from 0.3 to 5000 nM using an Evolution
P
3 robot liquid handling system (Perkin Elmer). The final DMSO
concentration was 0.1%. Luciferase activity was assayed after
24 hours. Sigmoidal dose-response curve-fitting and EC50
calculation was done by non-linear regression using GraphPad
Prism 4 (GraphPad Software, Inc).
Initial Screen
C2C12utrn cells were plated in 384-well plates 24 hours prior
to treatment with compounds. Compounds were added at a final
concentration of 2 mg/ml (approximately 5 mM based on an
average molecular weight of 400) using the Evolution P
3 robot
liquid handling system (Perkin Elmer). The final DMSO
concentration was 0.1%. Negative controls were treated with
0.1% DMSO only. Quality control (QC) plates were treated with
5 nM TSA. After 24 hours compound exposure, luciferase activity
was assayed as described above. QC plates were run at the
beginning and end of the assay. An algorithm for cross-talk
correction was applied. Data analysis was done using ActivityBase
(IDBS). The threshold for hits was set at 20% upregulation
(approximately 3 times the % CV of the negative controls).
Hit Confirmation and Dose Optimisation
For hit confirmation (dose-response I), C2C12utrn cells were
treated with each of the hits from the initial screen at 15
concentrations from 0.5 ng/ml to 8 mg/ml (approximately 1.6 nM
to 25 mM based on an average molecular weight for these 20
compounds of 316), to generate dose-response curves. The final
DMSO concentration remained constant at 0.4%. Otherwise, the
protocol was as described for the initial screen. For dose
optimisation (dose-response II), compounds were obtained in
greater quantity and dissolved in DMSO at 100 or 200 mM.
C2C12utrn cells were treated at 16 concentrations from 3.1 nM to
200 mM. The final DMSO concentration remained constant at
0.1%. The protocol was otherwise as for the initial screen.
Validation by Quantitative Real-Time PCR
C2C12 cells were plated in 6-well plates 24 hours prior to
treatment with nabumetone (25 mM). The final DMSO concen-
tration was 0.05%. Control cells were treated with 0.05% DMSO
only. After 24 hours compound treatment, cells were lysed and
RNA isolated using an RNeasy kit (Qiagen), following the
manufacturer’s protocol. RNA was reverse-transcribed using a
Superscript II First-Strand Synthesis kit (Invitrogen). A custom
TaqMan quantitative real-time PCR (qRT-PCR) assay for
utrophin A [31] was performed using 500 nM each of primers
59-ACGAATTCAGTGACATCATTAAGTCC-39 and 59-ATC-
CATTTGGTAAAGGTTTTCTTCTG-39 and 250 nM of FAM-
labelled MGB probe with sequence ATCATTGTGTTCATCA-
GATC, with 8 ng cDNA in a reaction volume of 25 ml. As an
endogenous control, 18S rRNA was amplified using pre-mixed
reagents from Applied Biosystems (Eukaryotic 18S rRNA
Endogenous Control (VIC/MGB probe, primer limited)), with
0.8 ng cDNA in a reaction volume of 50 ml. Other reaction
components were provided by Applied Biosystems TaqMan
Universal Mastermix. TaqMan qRT-PCR reactions were carried
out in 96-well plates using a 7300 Real-Time PCR System
(Applied Biosystems) and default thermocycler program. Analysis
was done using the DDCt method, having previously validated the
equal efficiencies of the two primer sets. Statistical analysis of
multiple independent experiments was done by one-way ANOVA
using Statview software (SAS Institute, Inc).
Validation by Western Blotting
Cells were plated in 60 mm dishes such that confluence was
approximately 25% the following day, at which point they were
treated with 25 mM nabumetone or vehicle (DMSO) only (0.1%)
for 4 days. After 2 days, cells were passaged and re-seeded in fresh
media with nabumetone or DMSO. After 4 days, cells were
trypsinised and resuspended in 300 ml TNEC lysis buffer (1.5 mM
Tris-HCl pH 8, 2.15 mM NaCl, 3.1% Igepal CA630, 4.2 mM
EDTA with Complete protease inhibitors (Roche)). Lysates were
incubated on ice for 20 minutes, centrifuged at maximum speed
for 10 minutes in a benchtop centrifuge at 4uC and supernatants
removed and stored at 220uC. The DC protein assay (Bio-Rad)
was used to determine total protein concentration. For Western
blotting, lysates containing 30 mg protein were combined with
LDS sample buffer and NuPAGE reducing agent and heated to
99uC for 5 minutes, then separated on 3–8% Tris-Acetate gels
(Invitrogen) with TA running buffer for 2 hours 15 minutes at
80 V. Proteins were transferred to PVDF membranes for 2 hours
at 80 V in ice-cooled transfer buffer (25 mM Tris pH 8.3,
192 mM glycine, 20% methanol, 0.05% sodium dodecyl sul-
phate). Membranes were blocked overnight at 4uC in 5% non-fat
milk in TBS (50 mM Tris pH 7.5, 150 mM NaCl), then probed
for utrophin with mouse monoclonal anti-utrophin antibody
mancho 3 clone 8A4 (developed by Glenn E. Morris and obtained
from the Developmental Studies Hybridoma Bank developed
under the auspices of the NICHD and maintained by The
University of Iowa Department of Biology) diluted 1:20 in 5%
non-fat milk in TBST (TBS with 0.05% Tween 20), for 1 hour at
room temperature. Blots were washed in 3 changes of TBST for
10 minutes each, then incubated with HRP-conjugated goat-anti-
mouse IgG (Jackson ImmunoResearch), diluted 1:4000 in 5% non-
fat milk in TBS, for 1 hour. TBST washes were repeated, then
bands were visualised using SuperSignal West Pico Chemilumi-
nescent Substrate (Thermo Scientific) and images obtained using
an LAS-3000 Imager (Fujifilm). Band densities were quantified
using ImageJ (http://rsbweb.nih.gov/ij/index.html). Statistical
analysis of multiple independent experiments was done by
Student’s T test using GraphPad Prism 5 (GraphPad Software,
Inc).
Results
Generation and Validation of C2C12utrn Stable Cell Line
The C2C12 mouse muscle cell line was selected for generation
of a stable cell line containing the human utrophin A promoter
linked to a luciferase reporter. Before making the cell line,
luciferase assays were performed with a known range of
concentrations of recombinant luciferase, in the presence or
absence of C2C12 cells. The presence of C2C12 cells had no
significant effect on the measured luciferase activity (Fig. S1A).
C2C12 cells were then transfected with a construct containing a
2.3 kb utrophin A promoter region linked to a luciferase reporter
gene. Hygromycin (250 mg/ml) was used to select stably
transfected cells, and resistant colonies were subjected to 2 rounds
of sub-cloning to obtain homogenous lines. Clones were validated
HTS for Utrophin Promoter Activation
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specific primers and genomic DNA as template (data not shown).
The clone with the greatest luciferase activity (named C2C12utrn)
was selected for development of a cell-based utrophin promoter
activation assay.
Utrophin Promoter Activation Assay Development
C2C12utrn cell number was optimised to 3000 cells per well,
which resulted in 70% confluence at the time of luciferase
quantification. DMSO is typically used as a solvent when
screening chemical libraries. To determine the tolerance of the
C2C12utrn cell line to DMSO, cells were treated with a range of
DMSO concentrations from 0–0.5% and their luciferase activity
was assayed. Concentrations of DMSO up to 0.2% had little effect
on measured luciferase activity. Above 0.2% DMSO, luciferase
activity declined but at 0.5% DMSO the activity was still 75% that
of cells without DMSO (Fig. S1B).
To find a positive control to assist in assay optimisation and to
examine the effects of different compound exposure times,
C2C12utrn cells were treated with four compounds previously
demonstrated to upregulate utrophin: L-arginine (2 mM) [32],
okadaic acid (50 nM) [33], heregulin (2 nM) [34] and trichostatin
A (TSA; 50 nM) (Bogdanovich et al., manuscript in preparation),
for 24 or 48 hours, before assaying for luciferase activity.
Incubation with TSA for 24 hours gave the greatest upregulation
of luciferase activity. For the other positive controls, the treatment
time did not affect the degree of promoter activation (Fig. 1A). To
determine the statistical robustness of the observed upregulation,
Z-factors were calculated for each positive control. Only TSA,
with 24 hours incubation, had a Z-factor indicative of suitability
for high-throughput screening (0.6; acceptable range 0.5–1) [35].
Additionally, the percentage covariance (% CV) was under 10%
and lower than for most other treatments (Table 1). Based on these
results, a compound exposure time of 24 hours was chosen for the
assay and TSA was selected as a positive control for further assay
development.
To further characterise the effect of TSA on C2C12utrn
luciferase activity and to confirm that the assay would translate to
Figure 1. Evaluation of positive controls and incubation times. A. C2C12utrn cells were treated for 24 or 48 hours with four compounds
known to upregulate utrophin, in 96-well format. The greatest upregulation (2-fold) was seen with trichostatin A (TSA) after 24 hours treatment. Bars
represent means 6 standard deviation. Dotted line represents control luciferase activity. * Different from untreated C2C12utrn cells (p,0.0001). B. A
dose-response curve was generated for treatment of C2C12utrn cells with TSA in 384-well format. The greatest response was seen at 20 nM and the
EC50 was 1.7 nM. Error bars represent standard deviation. RLU, relative luminescence units.
doi:10.1371/journal.pone.0026169.g001
HTS for Utrophin Promoter Activation
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for TSA in 384-well format using concentrations from 0.3 to
5000 nM. Non-linear regression was used to fit a sigmoidal dose-
response curve. From this, the EC50 was calculated to be 1.7 nM.
Peak luciferase activity occurred at 20 nM, above which the
activity declined, presumably due to cellular toxicity (Fig. 1B).
Cells are typically more susceptible to toxic effects in smaller sized
plate wells (unpublished observations). Z-factors and % CVs
calculated for TSA in 384-well format were similar to those
obtained in 96-well format (Table 2), confirming that the assay
would perform robustly in high-throughput screening.
Primary Screen of Prestwick Chemical Library
The utrophin promoter activation assay was used to screen the
Prestwick Chemical Library of approved drugs and natural
compounds. The compounds were screened at 2 mg/ml (approx-
imately 5 mM based on an average molecular weight of 400). The
control % CVs for the four plates were between 5.3 and 6.8%.
The threshold for hits was set at 20% upregulation (approximately
3 times the % CV of the controls, estimated to be low enough to
capture all true positive hits). Out of 1120 compounds, 20 hits
were obtained (1.8% of the library) with upregulation up to 80%
(1.8-fold; Fig. 2 and Table 3).
To confirm these hits, high-throughput dose-response curves
were generated, using 15 concentrations from 0.5 ng/ml to 8 mg/
ml (approximately 1.6 nM to 25 mM based on an average
molecular weight for these 20 compounds of 316). Of the 20
initial compounds, 14 showed dose-dependent activation of the
utrophin A promoter, confirming them as hits (dose-response I;
Fig. 3 and Table 3). These included 7 approved drugs and 7
natural compounds. Maximum fold-changes in utrophin A
promoter activity obtained during dose-response testing ranged
from 1.2 to 1.9 (Table 3). Dose-response curves were also
generated using a lower throughput, 96-well format (not shown).
Dose-dependent activity was confirmed, and fold-changes in
promoter activity between 1.9 and 3.5 were achieved.
For confirmed hits, stock solutions of higher concentration (100
or 200 mM) were obtained, and dose-response testing repeated
using concentrations up to 200 mM (dose-response II; Fig. 4 and
Table 3). Based on this, nabumetone, an FDA-approved drug that
showed high fold-changes and a lack of cellular toxicity (indicated
by a drop in luciferase activity at higher concentrations, e.g.
piperine, Fig. 4) was selected for independent validation.
Independent Validation
To confirm the effect of nabumetone on endogenous utrophin
promoter activity, normal C2C12 cells were treated with
nabumetone at its optimum concentration based on dose-response
testing, and utrophin A mRNA levels measured using a TaqMan
qRT-PCR assay. Treatment with nabumetone resulted in a
statistically significant, 1.8-fold increase in endogenous utrophin A
mRNA, compared to DMSO only controls (Fig. 5A).
As further validation, C2C12 cells were treated with nabume-
tone for 4 days, and utrophin protein levels were measured by
Western blotting. As shown in Fig. 5B–C, nabumetone treatment
resulted in a 1.2-fold increase in utrophin protein, confirming that
the observed upregulation of utrophin mRNA led to an increase in
protein levels.
Discussion
In this study, we present a novel utrophin promoter activation
assay, which we have used to screen a library of approved drugs
and natural compounds. After initial screening, hit confirmation
and independent validation, we have identified a lead com-
pound, nabumetone, that is a potential therapeutic candidate for
DMD.
The utrophin promoter activation assay performed well in tests
of robustness, with a Z-factor of 0.6 and % CV under 10%. The
number of hits as a percentage of the library (1.8%) was
comparable to other published screens [36,37,38], suggesting that
the assay was specific with a low number of false positives.
Nevertheless, we had set the initial screen threshold of 20%
upregulation low enough to avoid false negatives, in the
expectation that some of the initial hits would be false positives
due to ‘statistical noise’. Consistent with this, only 14 out of 20
initial hits (70%) were confirmed upon dose-response testing.
In screening assays that use luciferase as a reporter, false
positives can arise from compounds that act as luciferase
inhibitors. These compounds bind to and stabilise luciferase in
cells, increasing its levels, and are then competed off by the
substrate in the luciferase assay reagent, such that an artifactually
high luciferase activity is produced [39]. Thus, it is important to
independently confirm the effects of the hit compounds on the
endogenous utrophin A promoter, mRNA and protein. We did
this for one candidate, nabumetone, using a TaqMan qRT-PCR
assay for utrophin A mRNA and Western blotting for utrophin
protein. Validation of the remaining compounds is ongoing.
However, definitive in vitro validation experiments are challenging,
in part due to the differences in utrophin protein expression
compared to the in vivo situation, where utrophin is enriched at
specific locations, such as neuromuscular junctions [40,41,42], that
do not exist in cultured cells. To move our findings closer to the
Table 1. Determination of Z-factor and % CV for positive
controls.
Positive control 24 h treatment 48 h treatment
Z-factor % CV Z-factor % CV
L-arginine 211 0 20.3 7.6
Trichostatin A 0.6 3.6 28 7.8
Okadaic acid 20.1 7.5 0.06 4.1
Heregulin 20.3 7.5 0.08 3.5
C2C12utrn cells cultured in 96-well plates were exposed to L-arginine (2 mM),
TSA (50 nM), okadaic acid (50 nM) or heregulin (2 nM) for 24 or 48 hours before
assaying luciferase activity. Statistical robustness was assessed by calculating
the Z-factor and percentage covariance (% CV). Z-factors between 0.5 and 1
predict good performance in high-throughput screening.
doi:10.1371/journal.pone.0026169.t001
Table 2. Determination of Z-factor and % CV for TSA in 384-
well format.
TSA concentration (nM) Z-factor % CV
5 0.7 1.3
20 0.6 3.3
C2C12utrn cells cultured in 384-well plates were exposed to TSA at a range of
concentrations. Peak luciferase activity occurred at 20 nM. To determine
statistical robustness in 384-well format, the Z-factor and percentage
covariance (% CV) were calculated at 5 and 20 nM. Z-factors between 0.5 and 1
predict good performance in high-throughput screening.
doi:10.1371/journal.pone.0026169.t002
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compounds in vivo, using animal models of DMD.
Previous studies suggest that an increase of approximately 2-fold
in utrophin protein in muscle is sufficient for correction of the
dystrophic phenotype in mice [18]. In our study, we identified
several compounds that could upregulate the utrophin A promoter
up to 3.5-fold. Independent validation of nabumetone showed that
it could increase endogenous utrophin A mRNA levels approx-
imately 2-fold, and increase utrophin protein by 1.2-fold. This is
extremely promising given that even a very small upregulation of
utrophin appears to have a beneficial effect in dystrophin deficient
mice [18].
A variety of potential therapies for DMD are being investigated,
and some have reached clinical trials (http://www.clinicaltrials.
gov/). While this is greatly encouraging, there are still many
obstacles to be overcome before all patients with DMD can be
treated successfully. In many cases, problems of delivery, safety
and large-scale, cost-effective manufacture have not yet been
resolved. Some approaches, such as antisense oligonucleotide-
mediated exon-skipping and nonsense codon suppression, are only
applicable to subsets of patients with particular types of dystrophin
mutations [43,44]. Regulatory body approval may also be more
complicated for new kinds of drug molecules such as proteins and
oligonucleotides. For example, under current regulation, each of
the potentially hundreds [43] of mutation-specific exon-skipping
oligonucleotides would be treated as separate drugs [45]. It is also
important to consider that, initially at least, combinations of
treatments may be needed in order to achieve therapeutic efficacy.
Therefore, the continuation of research along multiple therapeutic
avenues, including utrophin upregulation, is of great importance
to ensure the development of effective therapies for all patients
with DMD.
There are a number of advantages to small molecule-mediated
utrophin upregulation that make it both a strong candidate for
DMD therapy and a complimentary approach to those discussed
above. The introduction of dystrophin protein into the body of a
DMD patient where it has never been expressed could provoke an
immune reaction against the protein, which might be recognised
Figure 2. Initial screen of Prestwick Chemical Library. The
utrophin promoter activation assay was used to screen the Prestwick
Chemical Library of approved drugs and natural products. Using a
threshold of 20% upregulation (dotted line), 20 out of 1120 compounds
were identified as hits (1.8%). Compounds confirmed as hits after dose-
response testing are represented by open squares.
doi:10.1371/journal.pone.0026169.g002





















Nabumetone Approved drug 228 1.8 8 1.6 25 2.6
Chrysin Natural 254 1.8 0.5 1.5 0.391 1.4
Piperine Natural 285 1.8 8 1.6 3.13 1.3
Apigenin Natural 270 1.7 1 1.5 0.781 1.5
Riluzole HCl Approved drug 234 1.7 1 1.6 25 2.0
Phenazopyridine HCl Approved drug 213 1.6 4 1.6 3.13 2.9
Resveratrol Natural 228 1.6 1 1.6 6.25 2.9
Tiabendazole Approved drug 201 1.6 4 1.9 12.5 2.2
Hesperetin Natural 302 1.5 8 1.9 100 2.8
Leflunomide Approved drug 270 1.4 1 1.4 12.5 1.8
Kawain Natural 230 1.4 4 1.4 100 2.5
Kaempferol Natural 286 1.4 8 1.8 not tested
{
Clorgyline HCl Approved drug 272 1.3 4 1.2 25 3.5
Equilin Component
* 268 1.2 8 1.6 100 2.4
*Component of approved drug.
{Concentration at which maximum fold-change was obtained.
{For technical reasons kaempferol was not tested to higher concentrations.
HCl, hydrochloride.
The 14 confirmed hits are presented with a summary of the fold-change (upregulation) in luciferase activity produced in each stage of testing with the assay, as well as
concentrations giving optimum activity. HCl, hydrochloride.
Supporting Information Legend.
doi:10.1371/journal.pone.0026169.t003
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PLoS ONE | www.plosone.org 6 October 2011 | Volume 6 | Issue 10 | e26169Figure 3. Hit confirmation: dose-response I. Dose-response curves were generated in 384-well format for the 20 compounds identified in the
initial screen, using concentrations from 0.5 ng/ml to 8 mg/ml. Fourteen molecules (nabumetone, chrysin, piperine, apigenin, riluzole HCl,
phenazopyridine HCl, resveratrol, tiabendazole, hesperetin, leflunomide, kawain, kaempferol, clorgyline HCl and equilin) showed dose-dependent
activity and were confirmed as hits. HCl, hydrochloride. RLU, relative luminescence units.
doi:10.1371/journal.pone.0026169.g003
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PLoS ONE | www.plosone.org 7 October 2011 | Volume 6 | Issue 10 | e26169Figure 4. Dose optimisation: dose-response II. Dose-response curves were generated in 384-well format for the 14 confirmed hits using
concentrations from 3.1 nM to 200 mM. HCl, hydrochloride. RLU, relative luminescence units.
doi:10.1371/journal.pone.0026169.g004
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high levels in other tissues such as liver, lung and kidney
throughout life in DMD patients (as well as healthy people)
[9,10], so increasing its production therapeutically in muscle
would not risk inciting an immune response. Additionally, the
utilisation of the endogenous utrophin gene provides an elegant
solution to problems arising from the large size of the dystrophin
coding sequence (14 kilobases) [46], which makes it difficult to
incorporate into viral vectors, except in truncated form. Finally,
the use of a traditional ‘drug-like’ small molecule, with favourable
absorption, distribution, metabolism and excretion properties
[47,48], to upregulate utrophin offers obvious advantages in terms
of delivery, stability and bioavailability.
Drug repositioning, the exploitation of existing drugs for new
applications, is becoming an increasingly important part of
research and development for the pharmaceutical industry
[27,28,29]. Our approach of screening a library of regulatory
body-approved drugs and natural compounds offers a distinct
advantage in terms of the speed and efficiency of future therapy
development. All the hits identified in our screen are compounds
that have been shown to be safe in humans, and for which
pharmacokinetic data is available. This eliminates a significant
proportion of the time and expense required when developing a
novel compound as a drug, and gives the potential for a rapid
progression from the lab to the clinic.
To date, we have validated one drug, nabumetone, at the
mRNA and protein level, in C2C12 cells. Nabumetone is a COX-
1/COX-2 inhibitor that shows a preference for COX-2 inhibition
in vitro [49]. It is used for the management of pain and
inflammation in osteoarthritis and rheumatoid arthritis [50].
Nabumetone is generally well-tolerated by patients [50], and its
anti-inflammatory activity might be beneficial in DMD, since
inflammation is a component of the disease [6,51,52]. There is
some evidence that the use of selective COX-2 inhibitors may
increase the risk of adverse cardiovascular events, especially in
patients who already have an increased risk [53,54,55]. This is less
of a concern with COX-1/COX-2 inhibitors, possibly because
COX-1 inhibition has an antiplatelet effect, which may protect
against thrombotic events [56]. Nonetheless, because of the
involvement of the heart in DMD pathology, the safety of
nabumetone use in this group would need to be carefully
evaluated.
In developing our assay, we used as positive controls a number
of substances already known to upregulate utrophin: heregulin,
TSA, okadaic acid and L-arginine. Of these, only L-arginine has
been used in human beings, as a supplement. There are some
safety concerns about its use, particularly at high dosages [57,58].
Its use in DMD patients has not been investigated.
In terms of doses, it is not possible to directly compare in vitro
and in vivo doses without considering pharmacokinetics; however,
using a crude calculation based on an average total human body
fluid volume of 42 l, the optimum dose for nabumetone
determined in cell culture (25 mM) lies far below that used in
human beings (equivalent to approximately 100–200 mM). As a
comparison, L-arginine was effective in activating our utrophin
upregulation assay at 2 mM, whereas doses used in humans would
correspond roughly to 0.2–5 mM.
In our experiments, we observed a smaller increase in utrophin
at the protein level than at the mRNA level. Although these
experiments were done at different time points to allow for the
expected slow synthesis of the large utrophin protein (approxi-
mately 400 kDa), this difference may also reflect the regulation of
utrophin at the translational level. Indeed, it is known that
utrophin expression is influenced by post-transcriptional mecha-
Figure 5. Independent validation of nabumetone. A. C2C12 cells
were treated with nabumetone (25 mM) or DMSO only for 24 hours.
Nabumetone produced a statistically significant, 1.8-fold increase in
utrophin A mRNA. Bars represent means of four independent
experiments 6 standard error. * Different from DMSO only controls
by Student’s T test (p,0.05). B. Representative Western blot showing
protein lysates from C2C12 cells treated with nabumetone or DMSO
only for 4 days, probed for utrophin with the antibody mancho3. A
single band was detected which migrated above the 250 kDa marker
(markers not shown). C. Quantification of utrophin band densities from
three independent Western blotting experiments, using ImageJ.
Nabumetone treatment resulted in a 1.2-fold increase in utrophin
protein. Bars represent means of 3 independent experiments, each
consisting of 3 nabumetone-treated and 3 DMSO only control samples,
6 standard error. * Different from DMSO only controls by Student’s T
test (p,0.05).
doi:10.1371/journal.pone.0026169.g005
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utrophin mRNA [59,60,61,62]. It may be that by combining drugs
that activate the utrophin promoter with therapies targeting points
of post-transcriptional expression control, or therapeutic substanc-
es such as biglycan that promote localisation and stabilisation of
utrophin at the sarcolemma [63], a far greater upregulation of
utrophin can be achieved.
In conclusion, we have taken a novel approach to the problem
of DMD therapy by screening existing drugs for utrophin
promoter activation. Following the successful screening project
and independent validation presented here, the lead compound
nabumetone will be tested in preclinical trials for its ability to
upregulate utrophin in vivo and improve the phenotype of
dystrophic mdx mice. This venture offers great promise for the
rapid development of an effective drug therapy for DMD.
However, we caution that although nabumetone is an FDA-
approved drug that is used safely in human beings, it will still be
important to conduct thorough preclinical studies in animals, as
well as clinical trials, to determine the safety and efficacy of its
long-term use in DMD.
Supporting Information
Figure S1 Development of utrophin promoter activation
assay. A. A standard curve with increasing concentrations of
recombinant luciferase was generated in the presence or absence
of normal C2C12 muscle cells. The presence of C2C12 cells had
no effect on luciferase activity, as tested by two-way ANOVA.
Error bars represent standard deviation. RLU, relative lumines-
cence units. B. C2C12utrn cells were treated with various
concentrations of DMSO for 48 hours and their luciferase activity
assayed. Luciferase activity declined above 0.2% DMSO but at
0.5% DMSO was still 75% that of cells without DMSO. Error
bars represent standard deviation.
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